About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome

The treatment combines SciSparc's Palmitoylethanolamide (PEA), the active pharmaceutical ingredient of its proprietary CannAmide, and Clearmind’s MEAI, a novel proprietary psychedelic treatment for various addictions

Tel Aviv, Israel, June 16, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that as part of the Company's ongoing collaboration with Clearmind Medicine Inc. (NASDAQ, CSE: CMND) ("Clearmind"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, a research agreement with the Hebrew University of Jerusalem was signed, to evaluate SciSparc's and Clearmind's proprietary combination treatment for obesity and metabolic syndrome.

Professor Joseph (Yossi) Tam, D.M.D., Ph.D., the Head of the Obesity and Metabolism Laboratory and the Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem, will lead the study using the proprietary combination of SciSparc's PEA, and Clearmind's Methoxy-2-aminoindane, or MEAI. "We are excited to continue our fruitful journey of scientific discovery alongside Clearmind Medicine and the esteemed Professor Joseph Tam of the Hebrew University of Jerusalem," stated Oz Adler, Chief Executive Officer of SciSparc. "We believe that the synergistic effect of our proprietary CannAmide™ and Clearmind's proprietary MEAI has immense potential in treating obesity and metabolic syndrome, two global health challenges of significant scale. This collaboration represents our ongoing commitment to delivering ground-breaking treatments that have the power to transform lives and improve global health outcomes."

A previous pre-clinical study using MEAI, conducted at the Hebrew University of Jerusalem, under the leadership of Prof. Tam, included multi-parameter metabolic assessments such as body weight, fat mass, glucose tolerance, insulin sensitivity, liver enzymes and fat accumulation as well as food consumption patterns. The study included three groups of rodents: lean rodents that were fed by a standard diet, obese rodents that were fed by a high-fat diet, and obese rodents that were fed by a high-fat diet along with MEAI treatment.

The results of the prior study showed that obese animals, fed by high fat diet and treated with MEAI increased their energy expenditure, demonstrated better fat utilization and had weight loss of 20%, while reducing their overall fat mass and preserving their lean body mass. No effect on motivation or well-being was observed. Additionally, the treatment yielded a normalization of insulin levels, improved glucose tolerance, and reduced fat and triglyceride accumulation in the liver. These results were significantly better than those obtained in the obese animals fed by high fat diet, untreated group.

Furthermore, a significant reduction in sucrose preference was observed following the administration of MEAI for two days, supporting the notion that it can potentially dampen the hedonic value of rewarding stimuli. Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behavior or excessive consumption of sweet foods.

About SciSparc Ltd. (Nasdaq: SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focusses on the sale of hemp seeds’ oil-based products on the Amazon.com marketplace.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses the Company’s potential of the synergistic combination of CannAmide™ and MEAI to treat obesity and metabolic syndrome, and MEAI’s potential to be beneficial for the treatment of compulsive reward-seeking behavior or to reduce excessive consumption of sweet foods. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 1, 2023, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.